TDZD-8

• Description:

  TDZD-8 is an inhibitor of GSK-3β, with an IC50 of 2 μM; TDZD-8 shows less potent activities against Cdk-1/cyclin B, CK-II, PKA, and PKC, with all IC50s of >100 μM.

• Product Name Alternative:

  GSK-3β Inhibitor I; NP 01139

• UNSPSC:

  12352005

• Hazard Statement:

  H334

• Target:

  GSK-3

• Type:

  Reference compound

• Related Pathways:

  PI3K/Akt/mTOR; Stem Cell/Wnt

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/TDZD-8.html

• Purity:

  99.76

• Solubility:

  DMSO : ≥ 100 mg/mL

• Smiles:

  O=C(N1CC2=CC=CC=C2)N(C)SC1=O

• Molecular Formula:

  C10H10N2O2S

• Molecular Weight:

  222.26

• Precautions:

  H334

• References & Citations:

  [1]Martinez A, et al. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem. 2002 Mar 14;45 (6) :1292-9.|[2]Xie CL, et al. Inhibition of Glycogen Synthase Kinase-3β (GSK-3β) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats. Sci Rep. 2016 Mar 21;6:23527.|[3]Sun A, et al. GSK-3β controls autophagy by modulating LKB1-AMPK pathway in prostate cancer cells. Prostate. 2016 Feb;76 (2) :172-83.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  GSK-3β

• CAS Number:

  [327036-89-5]